GI GILD Gilead Sciences Inc. Loading... : Bullish and Bearish Analyst Opinions

Moderna's flu vaccine (mRNA-1010) was refused filing by the FDA, but is progressing in Europe, Canada, and Australia. The company highlights a potential strain mismatch in the US vs. Northern Hemisphere, positioning its mRNA platform as a solution for better strain matching. — If Moderna secures approvals abroad, it could gain share in international markets while incumbents like Pfizer and GSK are locked into traditional strain selection, leading to a competitive advantage in vaccine efficacy.